AKTS News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

AK

Mkt Cap

$837.6M

Volume

341.35K

Next Earnings

November 12th

Loading chart

AK

AKTSAktis Oncology, Inc. Common stock

AKTS

Pay with—

Available Balance0.00

AK

Mkt Cap

$890.5M

Volume

341.35K

Next Earnings

November 12th

Chart Financials Earnings News About Insider Filings

Why This Biotech Fund Opened a $9 Million Position in a Newly Public Cancer CompanyAvidity Partners Management initiated a new $9.1 million position in Aktis Oncology (AKTS) during Q1 2026, acquiring 468,566 shares. The clinical-stage biotech company develops targeted radiopharmaceutical therapies for cancer using a proprietary miniprotein platform. With a strong balance sheet of $538.5 million in cash and clinical trials underway, Avidity's investment signals confidence in Aktis' potential as an emerging oncology player, though the company remains early in development.The Motley Fool · May 13, 2026

Aktis Oncology to Present at the BofA Securities Health Care ConferenceAktis Oncology announced that its President and CEO Matthew Roden will present at the BofA Securities Health Care Conference on May 13, 2026. The company is advancing its miniprotein radioconjugate platform for targeted radiopharmaceuticals, with lead programs AKY-1189 targeting Nectin-4 and AKY-2519 targeting B7-H3 across multiple solid tumor indications.GlobeNewswire Inc. · May 6, 2026

Aktis Oncology Announces Presentation of First Clinical Imaging and Dosimetry Data for AKY-2519 at the 2026 American Society of Clinical Oncology (ASCO) Annual MeetingAktis Oncology announced that clinical imaging and dosimetry data for AKY-2519, a miniprotein radioconjugate targeting B7-H3, will be presented in two poster presentations at the 2026 ASCO Annual Meeting in May. The FDA cleared IND applications for AKY-2519 in March 2026, enabling the company to proceed with a Phase 1b clinical trial starting mid-2026. AKY-2519 is the company's second clinical-stage miniprotein radioconjugate, following its lead program AKY-1189 targeting Nectin-4.GlobeNewswire Inc. · Apr 21, 2026

A Fresh IPO That Long-Term Investors Shouldn’t IgnoreAktis Oncology, a radiopharmaceutical biotech company, went public on January 9, 2026, raising $318 million in one of the largest recent biotech IPOs. The company specializes in targeted alpha radiopharmaceuticals for cancer treatment. With backing from Eli Lilly (which invested $100 million in shares), a growing nuclear medicine market projected to reach $35 billion by 2030, and an experienced management team, the stock may appeal to long-term investors despite being pre-revenue.Investing.com · Jan 14, 2026

Aktis Oncology Announces Closing of Upsized Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional SharesAktis Oncology, a clinical-stage oncology company focused on targeted radiopharmaceuticals, completed its upsized IPO on January 12, 2026, raising approximately $365.4 million gross proceeds. The company offered 17.65 million shares at $18.00 per share, with underwriters fully exercising their option to purchase an additional 2.65 million shares. Aktis began trading on Nasdaq under ticker symbol AKTS on January 9, 2026.Benzinga · Jan 13, 2026

Akoustis to Pursue Strategic Sale of its Business Through Voluntary Chapter 11 ProcessAkoustis Technologies, a manufacturer of RF filters, has filed for Chapter 11 bankruptcy to facilitate the sale of its business following a $59 million judgment against the company in a legal case with Qorvo. The company aims to continue operations during the sale process and ensure the business is sold free of any Qorvo infringement.GlobeNewswire Inc. · Dec 16, 2024

Akoustis Receives $2 Million in Volume Orders for Wi-Fi 7 Program from Tier-1 Carrier Charlotte, N.C., June 27, 2024 (GLOBE NEWSWIRE) -- Akoustis Technologies, Inc. (NASDAQ: AKTS) (“Akoustis” or the “Company”), an integrated device manufacturer (IDM) of patented bulk acoustic wave (BAW) high-band RF filters for mobile and other wireless applications, announced today that the company has received $2M in production orders from Tier-1 carrier customer to satisfy demand for two of its industry-leading XBAW® filters integrated into a Wi-Fi 7 platform.GlobeNewswire Inc. · Jun 27, 2024

Zacks Industry Outlook Highlights RF Industries and AkoustisRF Industries and Akoustis have been highlighted in this Industry Outlook article.Zacks Investment Research · Jun 24, 2024

2 Radio Frequency Stocks to Watch in a Challenging IndustryThe accelerated deployment of 5G is enhancing the prospects of the Zacks Semiconductors - Radio Frequency industry players like RF Industries (RFIL) and Akoustis Technologies (AKTS) despite challenging macroeconomic conditions.Zacks Investment Research · Jun 21, 2024

Should You Invest in Established or New Penny Stocks?Should you invest in either established or new penny stocks? The post Should You Invest in Established or New Penny Stocks? appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.PennyStocks · May 23, 2024

to start trading

AK

AKTSAktis Oncology, Inc. Common stock

AKTS

Pay with—

Available Balance0.00

Your PositionYou don't own any AKTS yet.

Related Tickers

Earnings